A PHASE I STUDY OF A COMBINATION OF YTTRIUM-90 LABELED HUMANIZED ANTI-CEA M5A

YTTRIUM-90 标记的人源化抗 CEA M5A 组合的 I 期研究

• 批准号: 7716670
• 负责人: JEFFREY Y WONG
• 金额: $ 2.28万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-20 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716670
• 关键词: 90Y; Anti-CEA Antibody; Antibodies; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Label; Maximum Tolerated Dose; Phase; Phase I Clinical Trials; Radioimmunoconjugate; Research; Research Personnel; Resources; Source; Therapeutic Agents; United States National Institutes of Health; chemotherapy; gemcitabine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A Phase I trial will evaluate the therapeutic agent Y-90-M5A-humanized anti-CEA antibody in combination with Gemcitabine chemotherapy. It will define the maximum tolerated dose of the radiolabeled antibody in combination with Gemcitabine. In addition, immunogenecity of the antibody will be assessed.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 I期试验将评估治疗剂Y-90-M5A人源化抗CEA抗体与吉西他滨化疗的结合。它将确定放射性标记抗体与吉西他滨联合使用的最大耐受量。此外，还将评估抗体的免疫原性。